公开(公告)号：US20220348964A1

公开(公告)日：2022-11-03

申请号：US17860833

申请日：2022-07-08

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin YU ,  Xavier de MOLLERAT du JEU

IPC: C12N15/86 ,  C12N7/00

Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.

公开(公告)号：US20180200374A1

公开(公告)日：2018-07-19

申请号：US15844380

申请日：2017-12-15

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Zhiwei YANG ,  Parul ANGRISH ,  Xavier de MOLLERAT du JEU ,  Kristin WIEDERHOLT

IPC: A61K47/54 ,  C07D211/58 ,  A61K48/00 ,  C12N15/88 ,  C12N15/113 ,  C07D211/28 ,  C07C229/08 ,  C07C227/06

CPC classification number: A61K47/54 ,  A61K47/543 ,  A61K48/0008 ,  C07C227/06 ,  C07C229/08 ,  C07D211/28 ,  C07D211/58 ,  C12N15/1137 ,  C12N15/88 ,  C12N2310/11 ,  C12N2310/141 ,  C07C229/26

Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

公开(公告)号：US20190201530A1

公开(公告)日：2019-07-04

申请号：US16230393

申请日：2018-12-21

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xavier de MOLLERAT du JEU ,  Nektaria ANDRONIKOU

IPC: A61K47/18 ,  A61K9/127 ,  A61K31/7105 ,  C12N15/88

CPC classification number: A61K47/186 ,  A61K9/1272 ,  A61K31/7105 ,  C12N15/88

Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.

公开(公告)号：US20180135077A1

公开(公告)日：2018-05-17

申请号：US15721105

申请日：2017-09-29

Applicant: Life Technologies Corporation

Inventor： Xin YU ,  Xavier de MOLLERAT du JEU

IPC: C12N15/86 ,  C12N7/00

CPC classification number: C12N15/86 ,  C12N7/00 ,  C12N2740/15043 ,  C12N2740/15052 ,  C12N2740/16043 ,  C12N2740/16051

Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.

公开(公告)号：US20230193214A1

公开(公告)日：2023-06-22

申请号：US18168396

申请日：2023-02-13

Applicant: Life Technologies Corporation

Inventor： Xin YU ,  Xavier de MOLLERAT du JEU ,  Chao Yan Lin ,  Jian Liu ,  Jonathan Zmuda

IPC: C12N7/00 ,  C12N1/06 ,  C12N15/86

CPC classification number: C12N7/00 ,  C12N1/06 ,  C12N15/86 ,  C12N2750/14041 ,  C12N2750/14152

Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

公开(公告)号：US20200270583A1

公开(公告)日：2020-08-27

申请号：US16798193

申请日：2020-02-21

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin YU ,  Xavier de MOLLERAT du JEU ,  Chao Yan Liu ,  jJian Liu ,  Jonathan Zmuda

IPC: C12N7/00 ,  C12N15/86 ,  C12N1/06

Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

公开(公告)号：US20190060482A1

公开(公告)日：2019-02-28

申请号：US16038107

申请日：2018-07-17

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Shikha MISHRA ,  Xavier de MOLLERAT du JEU

IPC: A61K47/69 ,  A61K9/127 ,  C12N9/22 ,  A61K31/7105 ,  A61K47/54 ,  A61P11/00

Abstract: Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, lung tissue without the requirement for biomolecular targeting.

公开(公告)号：US20240368564A1

公开(公告)日：2024-11-07

申请号：US18778386

申请日：2024-07-19

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin YU ,  Xavier de MOLLERAT du JEU ,  Chao Yan LIU ,  Jonathan ZMUDA ,  Jian LIU

IPC: C12N7/00 ,  C12N1/06 ,  C12N15/86

Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

公开(公告)号：US20220001023A1

公开(公告)日：2022-01-06

申请号：US17378466

申请日：2021-07-16

Applicant: Life Technologies Corporation

Inventor： Shikha MISHRA ,  Xavier de MOLLERAT du JEU

IPC: A61K47/69 ,  A61K9/127 ,  A61P11/00 ,  A61K31/7105 ,  A61K47/54 ,  C12N9/22 ,  C12N15/88 ,  A61K31/713 ,  A61K9/00

Abstract: Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, lung tissue without the requirement for biomolecular targeting.

公开(公告)号：US20210054415A1

公开(公告)日：2021-02-25

申请号：US17093486

申请日：2020-11-09

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin YU ,  Xiquan LIANG ,  Xavier de MOLLERAT du JEU ,  Robert Jason POTTER

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/88 ,  A61K48/00

Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.